EIF2AK3 and neoplasm: Interestingly, recent studies suggest that PERK-specific inhibitors may target dormant tumor cells resistant to conventional antiproliferative therapies, thus providing an adjuvant approach to eliminate minimal residual disease and prevent recurrence [17].